| Bioactivity | LSN3074753, an analog of LY3009120, is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation[1][2]. |
| CAS | 1455031-68-1 |
| Formula | C24H30FN5O2 |
| Molar Mass | 439.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yao YM, et al. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. [2]. Sorokin A, et al. Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer[J]. 2017. |
LSN3074753
CAS: 1455031-68-1 F: C24H30FN5O2 W: 439.53
LSN3074753, an analog of LY3009120, is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.